SAN DIEGO – The US Food and Drug Administration expects that its study to reproduce the results of randomized controlled trials using real-world evidence will fail to replicate in some instances – a result that could drive a better understanding of how to use claims and other real-world data.
Asked during a 25 June session of the DIA annual meeting, Center for Drug Evaluation and Research's David Martin acknowledged that the agency is not expecting complete replications.